Molecular prognostic markers in ovarian cancer: toward patient-tailored therapy

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
A P G CrijnsE G E de Vries

Abstract

In ovarian cancer the ceiling seems to be reached with chemotherapeutic drugs. Therefore a paradigm shift is needed. Instead of treating all patients according to standard guidelines, individualized molecular targeted treatment should be aimed for. This means that molecular profiles of the distinct ovarian cancer subtypes should be established. Until recently, most studies trying to identify molecular targets were single-marker studies. The prognostic role of key components of apoptotic and prosurvival pathways such as p53, EGFR, and HER2 has been extensively studied because resistance to chemotherapy is often caused by failure of tumor cells to go into apoptosis. However, it is more than likely that different ovarian cancer subtypes with extensive molecular heterogeneity exist. Therefore, exploration of the potential of specific tumor-targeted therapy, based on expression of a prognostic tumor profile, may be of interest. Recently, new profiling techniques, such as DNA and protein microarrays, have enabled high-throughput screening of tumors. In this review an overview of the current status of prognostic marker and molecular targeting research in ovarian cancer, including microarray studies, is presented.

References

Aug 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B FeinbergJ U Gutterman
Aug 22, 1995·International Journal of Cancer. Journal International Du Cancer·A BellacosaJ R Testa
Aug 26, 1993·Nature·J OgasawaraS Nagata
Nov 1, 1994·Trends in Biochemical Sciences·M A Lemmon, J Schlessinger
May 31, 1996·The Journal of Biological Chemistry·R M PittiA Ashkenazi
Oct 16, 1996·Journal of the National Cancer Institute·D F HayesR J Winn
Apr 4, 1997·Science·G PanV M Dixit
Jun 24, 1998·Proceedings of the National Academy of Sciences of the United States of America·P H ScottJ C Lawrence
Aug 28, 1998·Science·A Ashkenazi, V M Dixit
Nov 13, 1998·Science·M H CardoneJ C Reed
Jan 23, 1999·Nature Genetics·L ShayestehJ W Gray
Jun 9, 1999·Current Biology : CB·L P KaneA Weiss
Jun 23, 1999·Proceedings of the National Academy of Sciences of the United States of America·W H BiggsK C Arden
Jul 20, 1999·The Journal of Clinical Investigation·A AshkenaziR H Schwall
Sep 15, 1999·Nature·J A Romashkova, S S Makarov
Dec 2, 1999·Genes & Development·S R DattaM E Greenberg
Dec 1, 2000·Nature·B VogelsteinA J Levine
Feb 7, 2001·Proceedings of the National Academy of Sciences of the United States of America·J B WelshG M Hampton
Mar 17, 2001·Nature Reviews. Molecular Cell Biology·Y Yarden, M X Sliwkowski
Jul 17, 2001·Cancer Genetics and Cytogenetics·J TapperS Knuutila
Jul 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G N HortobagyiM C Hung
Aug 16, 2001·Proceedings of the National Academy of Sciences of the United States of America·L D Mayo, D B Donner
Aug 29, 2001·The Oncologist·M V Seiden
Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·T SørlieA L Børresen-Dale
Oct 5, 2001·Journal of the National Cancer Institute·S C MokD W Cramer
Dec 18, 2001·Journal of Nippon Medical School = Nippon Ika Daigaku Zasshi·M GhazizadehT Araki

❮ Previous
Next ❯

Citations

May 12, 2011·Der Radiologe·M Meissnitzer, R Forstner
Dec 11, 2008·Functional & Integrative Genomics·Alexander V SirotkinMilos Mlyncek
Jan 16, 2008·Current Treatment Options in Oncology·Shay Ashouri, Agustin A Garcia
Dec 14, 2011·Pathology Oncology Research : POR·Maria KoutsakiDemetrios A Spandidos
Jan 27, 2007·Molecular Cancer·Laura MenendezJohn F McDonald
Feb 6, 2009·PLoS Medicine·Anne P G CrijnsAte G J van der Zee
Mar 11, 2009·Frontiers in Bioscience (Landmark Edition)·Daniel G RosenJinsong Liu
Apr 7, 2010·Expert Opinion on Investigational Drugs·Liz Y HanStan B Kaye
Mar 2, 2016·Translational Research : the Journal of Laboratory and Clinical Medicine·Noor A LokmanCarmela Ricciardelli
Oct 23, 2014·Journal of Cancer Prevention·Jung-Yun LeeYong-Sang Song
Jul 12, 2011·The Journal of Pathology·Sophia Hl GeorgePatricia A Shaw
Mar 17, 2007·Pathology·Annie N Y Cheung
Jul 17, 2008·British Journal of Cancer·P de GraeffA G J van der Zee
Sep 4, 2007·The Oncologist·Rudolf S N FehrmannAnne P G Crijns
Feb 10, 2012·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·Chao LanWang Xiao

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis